CyDex Inc. is taking its drug-delivery vehicle to the animals.
CyDex, an Overland Park-based commercial spinoff from research at Kansas University, announced Tuesday that it had agreed to license its Captisol technology to Pfizer Inc. for use in animal health products.
Captisol a KU-created formulation system that led to CyDex's founding in 1993 already has been licensed to Pfizer for use in an antifungal compound being developed to treat humans. The latest licensure agreement is the company's first for Captisol's use in animal products.
"CyDex continues to broaden the applications of our technology to enhance the value of innovative new drugs," said Peter Higuchi, president and chief executive officer of CyDex.
Captisol boosts the stability and solubility of drug compounds for use in the body human or animal. Captisol originally was created at KU's Higuchi Biosciences Center for Drug Delivery Research, a center named for the late Takeru Higuchi, who had been a KU professor and is Peter Higuchi's father.
Privately-held CyDex already has licensed Captisol for use in a variety of products being developed by some of the largest companies in the industry, including Allergan Inc., Bristol-Myers Squibb, Daiichi Pharmaceutical Co. Inc., PTC Pharma AG, OSI Pharmaceuticals Inc. Suntory Ltd. and Genentech Inc.